[1] Schmitz S, Machiels J P. Molecular biology of squamous cell carcinoma of the head and neck relevance and therapeutic implications[J]. Expert Review of Anticancer Therapy, 2010, 10(9): 1471-1484.
[2] Athanassios A, Michalis V K, David R, et al. Head and neck cancer[J]. Lancet, 2008, 371: 1695-1709.
[3] Rezende T M, De Souza Freire M, Franco O L. Head and neck cancer: Proteomic advances and biomarker achievements[J]. Cancer, 2010, 116 (21): 4914-4925.
[4] Schaaij-Visser T B, Brakenhoff R H, Leemans C R, et al. Protein biomarker discovery for head and neck cancer[J]. Journal of Proteomics, 2010, 73(10): 1790-1803.
[5] Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J].CA: A Cancer Journal for Clinicians, 2005, 55(2): 74-108.
[6] Lee K D, Lee H S, Jeon C H. Body fluid biomarkers for early detection of head and neck squamous cell carcinomas[J]. Anticancer Research, 2011, 31(4): 1161-1167.
[7] Atkinson A J, Colburn W A, Degruttola V G, et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework[J]. Clinical Pharmacology & Therapeutics, 2001, 69(3): 89-95.
[8] Stransky N, Egloff A M, Tward A D, et al. The mutational landscape of head and neck squamous cell carcinoma[J]. Science, 2011, 333(6046): 1157-1160.
[9] Agrawal N, Frederick M J, Pickering C R, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1[J]. Science, 2011, 333(6046): 1154-1157.
[10] Martinez I, Wang J, Hobson K F, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas[J]. European Journal of Cancer, 2007, 43 (2): 415-432.
[11] Ralhan R, Masui O, Desouza L V, et al. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers[J]. Proteomics, 2011, 11(12): 2363-2376.
[12] Ralhan R, DeSouza L V, Matta A, et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy[J]. Journal of Proteome Research, 2008, 8(1): 300-309.
[13] Ralhan R, DeSouza L V, Matta A, et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry[J]. Molecular & Cellular Proteomics, 2008, 7(6): 1162-1173.
[14] Chi L M, Lee C W, Chang K P, et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated twodimensional LC-ESI-MALDI tandem MS[J]. Molecular & Cellular Proteomics, 2009, 8(7): 1453-1474.
[15] Wu Z, Doondeea J B, Gholami A M, et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer[J]. Molecular & Cellular Proteomics, 2011, 10(12): M111.011635.
[16] Jarai T, Maasz G, Burian A, et al. Mass spectrometry-based salivary proteomics for the discovery of head and neck squamous cell carcinoma[J]. Pathology & Oncology Research, 2012, 18(3): 623-628.
[17] George P. Metabolomics comes of age?[J]. The Scientist, 2005, 19(11): 8.
[18] Raamsdonk L M, Teusink B, Broadhurst D, et al. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations[J]. Nature Biotechnology, 2001, 19(1): 45-50.
[19] Gowda G N, Zhang S C, Gu H W, Asiago V, et al. Metabolomicsbased methods for early disease diagnostics[J]. Expert Review of Molecular Diagnostics, 2008, 8(5): 617-633.
[20] 和红兵, 石先哲, 陈静, 等. 气相色谱-质谱和液相色谱-质谱联用方法用于口腔癌代谢组学分析[J]. 色谱, 2012, 30(3): 245-251. He Hhongbin, Shi Xianzhe, Chen Jing, et al. Metabonomics study of oral cancer using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry[J]. Chinese Journal of Chromatography, 2012, 30(3): 245-251.
[21] Argiris A, Lee S C, Feinstein T, et al. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer[J]. Oral Oncology, 2011, 47 (10): 961-966.
[22] Ghannoum M A, Mukherjee P K, Jurevic R J, et al. Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: Toward novel diagnostic targets[J]. Omics: A Journal of Integrative Biology, 2013, 17(1): 5-15.
[23] Wei J, Xie G, Zhou Z, et al. Salivary metabolite signatures of oral cancer and leukoplakia[J]. International Journal of Cancer, 2011, 129 (9): 2207-2217.
[24] Srivastava S, Roy R, Gupta V, et al. Proton HR-MAS MR spectroscopy of oral squamous cell carcinoma tissues: An ex vivo study to identify malignancy induced metabolic fingerprints[J]. Metabolomics, 2010, 7 (2): 278-288.
[25] Somashekar B S, Kamarajan P, Danciu T, et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues[J]. Journal of Proteome Research, 2011, 10(11): 5232-5241.
[26] Koh T, Murakami Y, Tanaka S, et al. Changes of metabolic profiles in an oral squamous cell carcinoma cell line induced by eugenol[J]. In Vivo, 2013, 27(2): 233-243.
[27] Sepiashvili L, Hui A, Ignatchenko V, et al. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy[J]. Molecular & Cellular Proteomics, 2012, 11(11): 1404-1415.
[28] Barton R H, Nicholson J K, Elliott P, et al. High-throughput 1H NMR-based metabolic analysis of human serum and urine for largescale epidemiological studies: validation study[J]. International Journal of Epidemiology, 2008, 37(S1): i31-i40.
[29] Bernini P, Bertini I, Luchinat C, et al. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks[J]. Journal of Biomolecular NMR, 2011, 49(3/4): 231-243.
[30] Zhang A, Sun H, Wu X, et al. Urine metabolomics[J]. Clinica Chimica Acta, 2012, 414: 65-69.
[31] Want E J, Wilson I D, Gika H, et al. Global metabolic profiling procedures for urine using UPLC-MS[J]. Nature Protocols, 2010, 5 (6): 1005-1018.
[32] álvarez-Sánchez B, Priego-Capote F, Castro M D. Metabolomics analysis II. Preparation of biological samples prior to detection[J]. TrAC Trends in Analytical Chemistry, 2010, 29(2): 120-127.
[33] Fernández-Peralbo M A, Luque de Castro M D. Preparation of urine samples prior to targeted or untargeted metabolomics massspectrometry analysis[J]. TrAC Trends in Analytical Chemistry, 2012, 41: 75-85.
[34] Vuckovic D, Pawliszyn J. Systematic evaluation of solid-phase microextraction coatings for untargeted metabolomic profiling of biological fluids by liquid chromatography-mass spectrometry[J]. Analytical Chemistry, 2011, 83(6): 1944-1954.
[35] Vuckovic D. Current trends and challenges in sample preparation for global metabolomics using liquid chromatography-mass spectrometry[J]. Analytical and Bioanalytical Chemistry, 2012, 403(6): 1523-1548.
[36] Monteiro M S, Carvalho M, Bastos M L, et al. Metabolomics analysis for biomarker discovery: advances and challenges[J]. Current Medicinal Chemistry, 2013, 20(2): 257-271.
[37] López-Gresa M P, Maltese F, Bellés J M, et al. Metabolic response of tomato leaves upon different plant-pathogen interactions[J]. Phytochemical Analysis, 2010, 21(1): 89-94.
[38] Wang X, Sun H, Zhang A, et al. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies[J]. Journal of Separation Science, 2011, 34(24): 3451-3459.
[39] Spratlin J L, Serkova N J, Eckhardt S G. Clinical applications of metabolomics in oncology: A review[J]. Clinical Cancer Research, 2009, 15(2): 431-440.
[40] Somberg J C. Biomarker Methods in drug discovery and development[J]. American Journal of Therapeutics, 2009, 16(5): 466-467.
[41] Wang J H, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology[J]. Seminars in Nephrology, 2010, 30(5): 500-511.
[42] Putri S P, Yamamoto S, Tsugawa H, et al. Current metabolomics: Technological advances[J]. Journal of Bioscience and Bioengineering, 2013, 116(1): 9-16.
[43] Xiao J F, Zhou B, Ressom H W. Metabolite identification and quantitation in LC-MS/MS-based metabolomics[J]. Trends in Analytical Chemistry: TRAC, 2012, 32：1-14.
[44] Spagou K, Wilson I D, Theodoridis G. HILIC-UPLC-MS for exploratory urinary metabolic profiling in toxicological studies[J]. Analytical Chemistry, 2011, 83(1): 382-390.
[45] Spagou K, Tsoukali H, Raikos N, et al. Hydrophilic interaction chromatography coupled to MS for metabonomic/metabolomic studies[J]. Journal of Separation Science, 2010, 33(6/7): 716-727.
[46] Büscher J M, Czernik D, Ewald J C, et al. Cross-platform comparison of methods for quantitative metabolomics of primary metabolism[J]. Analytical Chemistry, 2009, 81(6): 2135-2143.
[47] 许国旺. 代谢组学：方法与应用[M]. 北京: 科学出版社, 2008. Xu Guowang, Metabonomics: Methods and application[M]. Beijing: Science Press, 2008.
[48] Yan S K, Wei B J, Lin Z Y, et al. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia[J]. Oral Oncology, 2008, 44(5): 477-483.
[49] 李丹娟. 鼻咽癌血清代谢组学初步研究[D]. 长沙: 中南大学, 2009. Li Danjuan. Research on serum metabonomics of the nasopharyngeal carcinoma[D]. Changsha: Central South University, 2009.
[50] Yao Z, Yin P, Su D, et al. Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter[J]. Molecular Biosystems, 2011, 7(9): 2608-2614.
[51] Tang F, Xie C, Huang D, et al. Novel potential markers of nasopharyngeal carcinoma for diagnosis and therapy[J]. Clinical Biochemistry, 2011, 44(8/9): 711-718.
[52] Leng J, Guan Q, Sun T, et al. Application of isotope-based carboxy group derivatization in LC-MS/MS analysis of tissue free-fatty acids for thyroid carcinoma[J]. Journal of Pharmaceutical and Biomedical Analysis, 2013, 84: 256-262.
